California is currently home to 5605 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Recruiting
The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2agonists. The investigators are interested in determining whether the large and/or small airways are the predominant site of airflow limitation. The investigators are also interested in determining whet... Read More
Gender:
ALL
Ages:
Between 10 years and 80 years
Trial Updated:
10/25/2023
Locations: Arthur F Gelb Medical Corporation, Lakewood, California
Conditions: Asthma
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
Recruiting
The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2agonists and long acting muscarinic antagonists. We are interested in determining whether the large and/or small airways are the predominant site of airflow limitation. We are also interested in determi... Read More
Gender:
ALL
Ages:
Between 10 years and 95 years
Trial Updated:
10/25/2023
Locations: Arthur F Gelb Medical Corporation, Lakewood, California
Conditions: Asthma
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
10/24/2023
Locations: ACTION3 Investigational Site 10, Northridge, California
Conditions: FSGS
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
Recruiting
Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide, doxorubicin, and prednisone in children, adolescent, and young adults with advanced peripheral T-cell lymphoma (non-anap... Read More
Gender:
ALL
Ages:
Between 1 year and 31 years
Trial Updated:
10/24/2023
Locations: Children's Hospital Orange County, Orange, California
Conditions: NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
Maintaining Behavior Change: An Evaluation of a Habit-based Sleep Health Intervention
Recruiting
The study will test a sleep-health intervention that leverages the science on habit formation. It will evaluate if adding a text messaging intervention improves habit formation. The participants will be 18-30 years old.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
10/23/2023
Locations: University of California, Berkeley, California
Conditions: Circadian Dysregulation
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
Recruiting
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML. The study consists of dose escalation (Part I) and dose expansion phase (Part II)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/23/2023
Locations: UCLA Medical cetner Division of Hematology, Los Angeles, California
Conditions: AML, Adult
Variations in Ketone Metabolism
Recruiting
This outcome of this study will elucidate how the phenotype of the individual modulates the KE metabolic effect. Most studies of KE have been in homogenous populations, usually young, male athletes. However, two striking experiments using identical, body weight adjusted KE doses in healthy and obese individuals found that BHB area under the curve (AUC) and removal was reduced by obesity and poor metabolic health. Similarly, ketone infusion experiments found that diabetes, obesity, and insulin re... Read More
Gender:
ALL
Ages:
Between 20 years and 70 years
Trial Updated:
10/19/2023
Locations: The Buck Institute, Novato, California
Conditions: Ketosis
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Recruiting
This is a Phase 1b/2a, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 in combination with atezolizumab administered to patients with advanced solid tumors (Part 1) and patients with Platinum-resistant Ovarian Cancer (Part 2)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: Sarcoma Oncology Center, Santa Monica, California
Conditions: Advanced Solid Tumor, Platinum-resistant Ovarian Cancer
Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis
Recruiting
In acute pancreatitis, approximately 20% of the cases result in severe necrotizing pancreatitis which is associated with significant morbidity and mortality. Necrotizing pancreatitis is characterized by the development of an acute necrotic collection and as this collection persists beyond 4 weeks, walled off necrosis (WON) encapsulates the collection. To date, this is treated by the step-up approach, which contains percutaneous drainage and minimally invasive video assisted retroperitoneal debri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: California Pacific Medical Center, San Francisco, California
Conditions: Acute Pancreatitis, Necrosis; Pancreas, Acute (Infectious)
A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis
Recruiting
ATLAS study is a clinical trial to evaluate the potential role of subcutaneous adrenocorticotropic hormone (ACTH) gel in the management of non-infectious scleritis. Specifically, the ATLAS Study aims to evaluate the safety, tolerability and effect of 2 different dose regimens of ACTH gel administered by subcutaneous (SC) injection in patients with scleritis, over a period of 12 months. Scleritis is an inflammatory disease affecting the sclera (white outer coating of the eye), which causes blur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: Byers Eye Institute, Stanford University, Palo Alto, California
Conditions: Scleritis
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: Velocity Clinical Research, Banning, California
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
EASE: The Materna Prep Pivotal Study
Recruiting
This study is designed to evaluate the safety and effectiveness of the Materna Prep Device in reducing pelvic muscle injuries during vaginal delivery. Subjects are randomized to Materna Prep Device or Standard of Care without use of the Materna Prep Device Intervention with the Materna Prep Device is expected to be a one-time use of approximately 30-90 minutes during the 1st stage of labor. Subject participation in the study is targeted to be 12 months from the time of the use of the device d... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: University of California Los Angeles, Los Angeles, California
Conditions: Vaginal Delivery, Pelvic Organ Prolapse